Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810575 · ClinicalTrials.gov registry record · Phase 2
Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction
A Phase 2 study, sponsored by Warner Chilcott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01810575: Clinical Trial Phase 2 study, sponsored by Warner Chilcott.
NCT01810575 is a Phase 2 study that was terminated before completion, run by Warner Chilcott. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01810575, a Phase 2 study, was terminated before completion, sponsored by Warner Chilcott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety \& efficacy of a single dose of alprostadil cream with 2 concentrations of WC3036 compared to vehicle alone in men with erectile dysfunction.
Primary Outcome
≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.
Interventions
- DRUG WC3036-11F/Alprostadil in Vehicle 2.5%
- DRUG WC3036-12F/Alprostadil in Vehicle 0.5%
- DRUG WC3036-13P/Vehicle Only 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Why NCT01810575 stopped before completion
NCT01810575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which WC3036-11F/Alprostadil in Vehicle 2.5% is the first listed.
NCT01810575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01810575 about?
NCT01810575 is a clinical study titled "Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction". The purpose of this study is to assess the safety \& efficacy of a single dose of alprostadil cream with 2 concentrations of WC3036 compared to vehicle alone in men with erectile dysfunction.
What is the current status of trial NCT01810575?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01810575?
The interventions under investigation include: WC3036-11F/Alprostadil in Vehicle 2.5% (DRUG), WC3036-12F/Alprostadil in Vehicle 0.5% (DRUG), WC3036-13P/Vehicle Only 0.5% (DRUG).
Who is sponsoring clinical trial NCT01810575?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01810575's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia